✦ LIBER ✦

Preclinical and Clinical Pharmacology of DOV 216,303, a “Triple” Reuptake Inhibitor

✍ Scribed by Phil Skolnick; Philip Krieter; Joseph Tizzano; Anthony Basile; Piotr Popik; Pal Czobor; Arnold Lippa

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

DOV 216,303, a “Triple” Reuptake Inhibit

✍ Beer, Bernard; Stark, Jill; Krieter, Philip; Czobor, Pal; Beer, Gary; Lippa, Arn 📂 Article 📅 2004 🏛 Sage Publications 🌐 English ⚖ 127 KB

The putative antidepressant DOV 216,303,

✍ Jolanda Prins; Damiaan A. Denys; Koen G. Westphal; Gerdien A. Korte-Bouws; Maria 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 499 KB

The triple monoaminergic reuptake inhibi

✍ M.E. Breuer; J.S.W. Chan; R.S. Oosting; L. Groenink; S.M. Korte; U. Campbell; R. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 482 KB

Preclinical pharmacology of TP1, a novel

✍ J.-W. Tian; W.-L. Jiang; Y. Zhong; Q. Meng; Y. Gai; H.-B. Zhu; J. Hou; Y. Xing; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 813 KB

The potential and limitations of DOV 216

✍ J. Prins; K.G.C. Westphal; G.A.H. Korte-Bouws; M.S. Quinton; R. Schreiber; B. Ol 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 915 KB

The triple reuptake inhibitor DOV 216,30

✍ Jolanda Prins; Paul J. Kenny; Ivo Doomernik; Rudy Schreiber; Berend Olivier; S. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 441 KB